Kavanagh David, Richards Anna, Noris Marina, Hauhart Richard, Liszewski M Kathryn, Karpman Diana, Goodship Judith A, Fremeaux-Bacchi Veronique, Remuzzi Giuseppe, Goodship Timothy H J, Atkinson John P
Division of Rheumatology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Mol Immunol. 2008 Jan;45(1):95-105. doi: 10.1016/j.molimm.2007.05.004. Epub 2007 Jun 26.
Recent studies have identified mutations in the complement regulatory gene factor I (CFI) that predispose to atypical hemolytic uremic syndrome (aHUS). CFI is a two-chain serine protease in which the light chain carries the catalytic domain while the heavy chain's function is unclear. It downregulates the alternative and classical complement pathways by cleaving the alpha' chains of C3b and C4b in the presence of cofactor proteins (known as cofactor activity). Many CFI mutations in aHUS result in low CFI levels with a consequent quantitative defect in complement regulation. In others, the mutant protein is present in normal amounts but the presumed functional deficiency has not yet been defined. In this report we examine the nature of the functional defect in aHUS-associated CFI mutations. The I322T, D501N and D506V mutations reside in the serine protease domain of CFI and result in secreted proteins that lack C3b and C4b cofactor activity. The delTTCAC (1446-1450) mutant leads to a protein that is not secreted. The R299W mutant lies in a region of the CFI heavy chain of no known function. Our assessments demonstrate decreased C3b and C4b cofactor activity, providing evidence that this region is important for cofactor activity. In two other heavy chain mutants and one probable polymorphic variant, no functional deficiency was identified. These defective mutant proteins will result in an inability to appropriately control the complement cascade at sites of endothelial cell injury. The excessive complement activation for a given degree of damage may result in generation of a procoagulant state and aHUS.
最近的研究已经确定了补体调节基因因子I(CFI)中的突变,这些突变易导致非典型溶血性尿毒症综合征(aHUS)。CFI是一种双链丝氨酸蛋白酶,其中轻链携带催化结构域,而重链的功能尚不清楚。它通过在辅因子蛋白(称为辅因子活性)存在的情况下切割C3b和C4b的α'链来下调替代和经典补体途径。aHUS中的许多CFI突变导致CFI水平降低,从而在补体调节中出现定量缺陷。在其他情况下,突变蛋白以正常量存在,但假定的功能缺陷尚未确定。在本报告中,我们研究了aHUS相关CFI突变中功能缺陷的性质。I322T、D501N和D506V突变位于CFI的丝氨酸蛋白酶结构域中,导致分泌的蛋白质缺乏C3b和C4b辅因子活性。delTTCAC(1446-1450)突变体导致一种不分泌的蛋白质。R299W突变位于CFI重链中一个功能未知的区域。我们的评估表明C3b和C4b辅因子活性降低,这证明该区域对辅因子活性很重要。在另外两个重链突变体和一个可能的多态性变体中,未发现功能缺陷。这些有缺陷的突变蛋白将导致在内皮细胞损伤部位无法适当控制补体级联反应。对于给定程度的损伤,过度的补体激活可能导致促凝状态和aHUS的产生。